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cardiovascular disease (ASCVD). 1 Moreover, even with high-dose statin therapies, the residual risk of major adverse cardiovascular events still exists. 2 Studies have indicated that many factors, such as dyslipidemia, smoking, hypertension, diabetes, metabolic disorder, and alcohol, account for most of the risk of vascular events. Dyslipidemia is the major factor among these risks. 3 Lowering LDL-C levels by statins reduces cardiovascular events after acute coronary syndrome, 4 while dyslipidemia is characterized by high triglyceride (TG) and low highdensity lipoprotein cholesterol (HDL-C) levels, and an accumulation of cholesterol-rich remnant particles with high levels of apolipoprotein B. 5 Although lowering the LDL-C level in these patients is the primary goal, in order to reduce cardiovascular risk, 6 recent therapy guidelines have emphasized consideration of other lipoprotein abnormalities as well as non-lipid risk factors (including smoking, blood pressure, and weight management) that contribute to global risk. 7 There are also patients who have no response or sensitivity to monotherapy drugs, such as statins, because of their own physical fitness. Furthermore, high-dose monotherapy statins can increase the incidence of adverse drug events as well as therapy costs and they can be hard for some patients to tolerate.
This study aimed to find other lipid-lowering drugs to evaluate the effect and safety from all of the available data. 
| MATERIALS AND METHODS

| Search strategy
We searched the major medical databases, such as PubMed, Embase, Ovid, ScienceDirect, Springer, and Web of Science, for randomized controlled trials (RCTs) comparing combination lipid-lowering therapies based on statin treatment with statin monotherapies for major cardiovascular events. We included articles published from January 2000 to April 2018, and the search terms used were: "statin monotherapies", "combination", "ASCVD", "lipid-lowering therapies", "randomized controlled trial" and so on.
| Criteria selection and data extraction
Inclusion criteria were as follows: (a) RCT study design, (b) recruited patients had ASCVD or were at high risk of ASCVD, (c) study compared statin monotherapies with combination therapy based on statin, (d) article reported the data of major adverse cardiovascular events, and (e) entire follow-up intervals were ≥6 weeks.
Data were abstracted using predefined data fields. The following data were extracted from each study: details of participant characteristics (age, sex, basic disease, and lifestyle), the number of patients in each group, duration of follow-up, baseline lipid levels (including TC, LDL-C, HDL-C, and TG), treatment and drug dosage, incidence of adverse events, and the percent of attaining goals.
| Statistical analysis
Standard mean difference (SMD) and risk ratio (RR) were used for the analysis of continuous and dichotomous variables, respectively.
The chi-square test was used to evaluate heterogeneity among the studies, and I 2 was used to quantify the inconsistency. There were two models: the fixed effect model and the random effect model. The fixed effect model was used when the effects were deemed to be homogeneous (P > 0.1, I 2 < 50%); otherwise, the random effects model was used. The Z test was used to compare the overall difference. The confidence interval (CI) was established at 95%, and P values < 0.05 were considered to indicate statistical significance. Begg's test and Egger's test were performed in order to evaluate the publication bias (in Begg's test P > 0.05 and in Egger's test P > 0.05 and 95% CI includes 1; it is thought that there was no publication bias).
Statistical analyses were performed using STATA 12.0 (meta module;
StataCorp., College Station, TX, USA).
| RESULTS
| Characteristics of study selection
In total, 12 papers of RCTs that compared statin monotherapies with combination therapies were selected. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] The characteristics of each RCT are presented in Table 1 . This meta-analysis included 6227 patients with ASCVD risk, 3108 of whom were given statin plus another drug therapy (including coenzyme A, ezetimibe, niacin, and fenofibrate) and 3119 of whom were given statin monotherapy. goal of therapy and a target non-HDL-C < 130 mg/dL as the secondary goal of therapy if elevated TG was coexisting. 6 There are four studies 11, 12, 15, 16 comparing the percent of attaining LDL-C goals between two groups ( Figure 1 ) and three studies 11, 15, 16 Foody et al 23 found that combination ezetimibe/statin therapy improves goal attainment and reduces the use of high-potency or high-dose statins in high risk of cardiovascular disease. This is also testified in this article.
|
| Change of lipid level
The final LDL-C level reduced more significantly from baseline in the combination group than in the statin monotherapy group (Figure 3 ).
Data collected from 10 studies [11] [12] [13] [14] [15] 17, 18, [20] [21] [22] show a greater change level in combination therapy (z = 2.80, P = 0.005). The final HDL-C level in the combination group increased more from baseline than that in statin monotherapy (Figure 4 ). Data collected from 10 studies [11] [12] [13] [14] [15] 17, 18, [20] [21] [22] show a greater change level in combination therapy (z = 17.62, P = 0.000). The final TG level in the combination group reduced less from baseline than that in statin monotherapy (Figure 5 ). Data collected from six studies 11, 12, 14, 15, 17, 20 show a greater change level in combination therapy (z = 3.41, P = 0.001).
LDL-C response is typically dependent on baseline LDL-C and inversely related to baseline TG. Many studies proved that the reduction of LDL-C was remarkable with combination therapy.
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| Adverse events
Four trials [13] [14] [15] 17 reported the incidence of drug-related adverse events ( Figure 6 ) and four trials 13, 14, 16, 17 15 Tsujita et al 18 Torimoto et al 12 Weinstein et al 14 AIM-HIGH Investigators et al 21 Davidson et al 17 Taylor et al 20 
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Insull et al 13 Kastelein et al 22 Lai 17 Lai et al 11 Torimoto et al 12 Weinstein et al 14 Taylor et al 20 Farnier Ezetimibe primarily reduces LDL-C levels (19%), with more modest reductions in TG (8%) and increases in HDL-C (3%) in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. 28 Niacin primarily increases HDL-C levels (15%-35%), and to a lesser extent reduces triglycerides (20%-50%), with moderate LDL-C-lowering effects (5%-25%). 29, 30 Omega-3 fatty acids are effective agents for lowering TG. The GISSI-Prevenzione trial showed that dietary supplementation with omega-3 fatty acids reduced mortality by 20% in survivors of myocardial infarction. 31 The percent reductions in LDL-C level in ezetimibe/rosuvastatin combination groups were more than 50% from baseline. 27 The addition of niacin, omega-3 fatty acids, or fibrates to statin therapy has produced their expected additive lipid effects but has failed to achieve a clinical benefit. Adding ezetimibe to statin therapy can further lower LDL-C safely and translate into a clinical benefit in patients at high risk of cardiovascular events. 32 Adding fenofibric acid had a modest, incremental, favorable effect on LDL-C, non-HDL-C, total cholesterol, and hypersensitive C-reactive protein between moderate-and low-dose combination therapy, and the effect on TG and HDL-C was similar whether fenofibric acid was combined with a moderate-or low-dose statin.
| DISCUSSION
This was expected as only the statin dose was increased. Higherdose combination therapy does not provide additional benefits on TG and HDL-C. 33 There is no need to increase the dose of statin if statin monotherapy fails to attain the treatment goals, and a moderate dose should suffice. High-dose statin generates the same effect with the moderate dose, but increases the incidence of adverse events. Additional appropriate lipid-modified drug combination therapy can be used according to the patient's blood lipid level.
Combination therapy can lower LDL-C and TG and increase HDL-C more effectively, but will not reduce the risk of adverse cardiovascular events. Thus, in a clinical context, this treatment must be selected carefully.
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